Lorbrena (lorlatinib)

pCPA File Number: 21182
Negotiation Status:
Negotiations were not pursued
Indication(s):
Non-Small Cell Lung Cancer (ALK+)
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0183-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: